Last update 01 Nov 2024

Incyte Biosciences Distribution BV

Subsidiary Company|
Netherlands

Overview

Tags

Other Diseases
Neoplasms
Hemic and Lymphatic Diseases
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms5
Hemic and Lymphatic Diseases4
Nervous System Diseases3
Immune System Diseases3
Infectious Diseases2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug3
Monoclonal antibody2
Top 5 TargetCount
FGFR1 x FGFR2 x FGFR31
JAK1 x JAK21
PD-1(Programmed cell death protein 1)1
Bcr-Abl x Tyrosine kinase1
CD19(B-lymphocyte antigen CD19)1

Related

5
Drugs associated with Incyte Biosciences Distribution BV
Retifanlimab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
MacroGenics, Inc.MacroGenics, Inc. [+6]
Originator Org.
MacroGenics, Inc.MacroGenics, Inc.
Active Indication
Metastatic Merkel Cell Carcinoma [+32]
Inactive Indication
Locally Advanced Renal Cell Carcinoma [+12]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date22 Mar 2023
Tafasitamab-Cxix
Target
CD19
Mechanism
CD19 inhibitors [+2]
Active Org.
Incyte Corp.Incyte Corp. [+6]
Originator Org.
Xencor, Inc.Xencor, Inc.
Active Indication
Diffuse large B-cell lymphoma recurrent [+19]
Inactive Indication
Burkitt Lymphoma [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date31 Jul 2020
Pemigatinib
Target
FGFR1 x FGFR2 x FGFR3
Mechanism
FGFR1 antagonists [+2]
Active Org.
Incyte Biosciences Distribution BV [+6]
Originator Org.
Incyte Corp.Incyte Corp.
Active Indication
Advanced Bile Duct Carcinoma [+18]
Inactive Indication
Advanced cancer [+11]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date17 Apr 2020
6
Clinical Trials associated with Incyte Biosciences Distribution BV
CTR20241368 / RecruitingPhase 3
一项评价Tafasitamab和来那度胺联合吉西他滨和奥沙利铂对比利妥昔单抗联合吉西他滨和奥沙利铂治疗复发/难治性弥漫性大B细胞淋巴瘤患者的有效性和安全性的随机、多中心、III期临床研究
[Translation] A randomized, multicenter, phase III clinical study to evaluate the efficacy and safety of tafasitamab and lenalidomide combined with gemcitabine and oxaliplatin versus rituximab combined with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
CTR20221519 / Active, not recruitingPhase 2
一项评价Tafasitamab联合来那度胺治疗复发或难治性弥漫性大B细胞淋巴瘤患者安全性和有效性的单臂、开放、多中心II期临床研究
[Translation] A single-arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of Tafasitamab combined with Lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma
CTIS2024-512331-72-00 / Not yet recruiting
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
100 Clinical Results associated with Incyte Biosciences Distribution BV
Login to view more data
0 Patents (Medical) associated with Incyte Biosciences Distribution BV
Login to view more data
100 Deals associated with Incyte Biosciences Distribution BV
Login to view more data
100 Translational Medicine associated with Incyte Biosciences Distribution BV
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
5
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free